In this project, one NSCLC cohorts were analyzed by Data Independent Acquisition (DIA-MS). A cohort of early stage NSCLC samples (207) with the aim to demonstrate utility of MS for subtyping and treat
BackgroundAs the crosstalk between metabolism and antitumor immunity continues to be unraveled, we aim to develop a prognostic gene signature that integrates lipid metabolism and immune features for p
Supplementary Table 5. Drug perturbation and OncoTreat analysis A. Summary of drugs and concentrations used B. Drug perturbation data for DU145 C. OncoTreat for drugs to SU2C patients using DU145 D. O
